These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12555357)

  • 41. Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy.
    Wan C; Warner M; De Varennes B; Ergina P; Cecere R; Lachapelle K
    Ann Thorac Surg; 2006 Jul; 82(1):21-6. PubMed ID: 16798180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
    Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
    Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
    Gurbuz AT; Elliott WG; Zia AA
    Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
    Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
    Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heparin-induced thrombocytopenia in hemodialysis patients.
    Brouwer DJ; Peterson P
    Nephrol Nurs J; 2000 Apr; 27(2):240-1, 213. PubMed ID: 11111553
    [No Abstract]   [Full Text] [Related]  

  • 46. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin-induced thrombocytopenia and thrombosis.
    Patel VP; Bong M; Di Cesare PE
    Am J Orthop (Belle Mead NJ); 2007 May; 36(5):255-60. PubMed ID: 17571830
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Anticoagulants in clinical practice].
    Boneu B
    Rev Prat; 1999 Oct; 49(15):1641-7. PubMed ID: 10581994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery.
    Ronchard T; Salaun E; Theron A; Grisoli D; Jaussaud N; Collart F; Habib G; Camoin-Jau L
    Ann Thorac Surg; 2017 Jan; 103(1):e9-e10. PubMed ID: 28007287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of heparin-induced thrombocytopenia.
    Dager WE; White RH
    Ann Pharmacother; 2002 Mar; 36(3):489-503. PubMed ID: 11895064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 53. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium.
    Pouplard C; Amiral J; Borg JY; Vissac AM; Delahousse B; Gruel Y
    Br J Haematol; 1997 Nov; 99(2):273-80. PubMed ID: 9375738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of heparin-induced thrombocytopenia.
    Peters FP
    J Thorac Cardiovasc Surg; 1997 Sep; 114(3):517-8. PubMed ID: 9305220
    [No Abstract]   [Full Text] [Related]  

  • 55. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia.
    Bartholomew JR
    Chest; 2005 Feb; 127(2 Suppl):27S-34S. PubMed ID: 15706028
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
    Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
    Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
    [No Abstract]   [Full Text] [Related]  

  • 57. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
    Cuker A; Arepally GM; Chong BH; Cines DB; Greinacher A; Gruel Y; Linkins LA; Rodner SB; Selleng S; Warkentin TE; Wex A; Mustafa RA; Morgan RL; Santesso N
    Blood Adv; 2018 Nov; 2(22):3360-3392. PubMed ID: 30482768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia.
    Greinacher A
    Semin Thromb Hemost; 2004 Jun; 30(3):315-27. PubMed ID: 15282654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR; Hickton C; Henderson S; Patton WN
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Current status of anticoagulants].
    Oger E; Mottier D
    Presse Med; 2000 May 27-Jun 3; 29(19):1079-82. PubMed ID: 10874921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.